Acurx Pharmaceuticals Announced Efficacy Results From The Phase 2 Trial Of Ibezapolstat For C. Difficile Infection, With 96% Clinical Cure Rate In Patients
Portfolio Pulse from Benzinga Newsdesk
Acurx Pharmaceuticals has announced the efficacy results from the Phase 2 trial of Ibezapolstat for C. Difficile infection, with a 96% clinical cure rate in patients after 10 days of oral treatment. The trial met its primary objective of assessing the primary efficacy endpoint.
November 02, 2023 | 11:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acurx Pharmaceuticals' Phase 2 trial of Ibezapolstat has shown a 96% clinical cure rate for C. Difficile infection. This positive result could potentially boost the company's stock in the short term.
The successful Phase 2 trial of Ibezapolstat, with a high clinical cure rate, indicates a positive development for Acurx Pharmaceuticals. This could potentially lead to regulatory approval and commercialization of the drug, which would likely have a positive impact on the company's revenues and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100